Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
The DNA sensor AIM2 mediates psoriasiform inflammation by inducing type 3 immunity
Timna Varela Martins, Bruno Marcel Silva de Melo, Juliana Escher Toller-Kawahisa, Gabriel Victor Lucena da Silva, Conceição Elidianne Aníbal Silva, Isadora Marques Paiva, Gabriel Azevedo Públio, Marcos Henrique Rosa, Cacilda da Silva Souza, Dario Simões Zamboni, Fernando Q. Cunha, Thiago Mattar Cunha, Bernhard Ryffel, Nicolas Riteau, José C. Alves-Filho
Timna Varela Martins, Bruno Marcel Silva de Melo, Juliana Escher Toller-Kawahisa, Gabriel Victor Lucena da Silva, Conceição Elidianne Aníbal Silva, Isadora Marques Paiva, Gabriel Azevedo Públio, Marcos Henrique Rosa, Cacilda da Silva Souza, Dario Simões Zamboni, Fernando Q. Cunha, Thiago Mattar Cunha, Bernhard Ryffel, Nicolas Riteau, José C. Alves-Filho
View: Text | PDF
Research Article Inflammation

The DNA sensor AIM2 mediates psoriasiform inflammation by inducing type 3 immunity

  • Text
  • PDF
Abstract

Psoriasis is a chronic and recurrent inflammatory skin disease characterized by abnormal proliferation and differentiation of keratinocytes and activation of immune cells. However, the molecular driver that triggers this immune response in psoriatic skin remains unclear. The inflammation-related gene absent in melanoma 2 (AIM2) was identified as a susceptibility gene/locus associated with psoriasis. In this study, we investigated the role of AIM2 in the pathophysiology of psoriasis. We found elevated levels of mitochondrial DNA in patients with psoriasis, along with high expression of AIM2 in both the human psoriatic epidermis and a mouse model of psoriasis induced by topical imiquimod (IMQ) application. Genetic ablation of AIM2 reduced the development of IMQ-induced psoriasis by decreasing the production of type 3 cytokines (such as IL-17A and IL-23) and infiltration of immune cells into the inflammatory site. Furthermore, we demonstrate that IL-17A induced AIM2 expression in keratinocytes. Finally, the genetic absence of inflammasome components downstream AIM2, ASC, and caspase-1 alleviated IMQ-induced skin inflammation. Collectively, our data show that AIM2 is involved in developing psoriasis through its canonical activation.

Authors

Timna Varela Martins, Bruno Marcel Silva de Melo, Juliana Escher Toller-Kawahisa, Gabriel Victor Lucena da Silva, Conceição Elidianne Aníbal Silva, Isadora Marques Paiva, Gabriel Azevedo Públio, Marcos Henrique Rosa, Cacilda da Silva Souza, Dario Simões Zamboni, Fernando Q. Cunha, Thiago Mattar Cunha, Bernhard Ryffel, Nicolas Riteau, José C. Alves-Filho

×

Figure 6

ASC and caspase-1 are required for the development of IMQ-induced psoriasis in mice.

Options: View larger image (or click on image) Download as PowerPoint
ASC and caspase-1 are required for the development of IMQ-induced psoria...
(A) PYCARD and CASP1 gene expression in skin biopsy samples from healthy control and nonlesioned or lesioned sites from patients with psoriasis evaluated by analysis of a published transcriptomic dataset (GSE14905). (B–E) WT, Aim2–/–, Pycard–/–, and Casp1–/– mice after 6 days of IMQ treatment. Untreated WT mice were used as controls. (B) Kinetics of relative mRNA expression of Casp1 and Il1b in the whole skin lysates from IMQ-treated WT mice normalized to Gapdh evaluated by qPCR (n = 6 per group). (C) Time course of changes in the back skin thickness (Δ) measured daily after topical IMQ application by caliper (n = 6 per group). (D) Representative H&E staining from back skin sections. Images were acquired at 20× magnification. Scale bar: 100 μm (n = 6 per group). (E) IL-1β, IL-17, and IL-23 concentration in skin homogenates determined by ELISA (n = 6 per group). Data are representative of 2 independent experiments and are shown as mean ± SEM. Statistical significance was evaluated by 1-way ANOVA with Bonferroni post hoc test in A and E, and 2-way ANOVA followed by Bonferroni’s post hoc test in B and C. *P < 0.05 and ****P < 0.0001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts